Parkinson’s Disease News and Research RSS Feed - Parkinson’s Disease News and Research

Perceived cost affects placebo response in Parkinson’s disease

Perceived cost affects placebo response in Parkinson’s disease

Patients with Parkinson’s disease may gain a greater benefit from a placebo treatment if they believe it to be expensive, research suggests. [More]
Patients with Parkinson's disease often face difficulties with reduced visual contrast acuity

Patients with Parkinson's disease often face difficulties with reduced visual contrast acuity

Patients with Parkinson's disease (PD) often have difficulties with visual acuity in low-contrast images. Because they may have normal high-contrast vision, this is often overlooked during routine eye exams. In the current issue of the Journal of Parkinson's Disease, researchers report that PD patients had significantly worse vision for low-contrast images at close (40 cm) and far (2 m) distances. Even for high-contrast images, PD patients' vision was deficient at far distances. [More]
UK scientists find new approach to treat Parkinson's disease

UK scientists find new approach to treat Parkinson's disease

UK scientists have developed a peptide that sticks to the protein that causes Parkinson's disease, stopping it from killing brain cells. The research highlights a potential new route for slowing the progress of this incurable disease. [More]
Prexton closes €8.7 million in Series A financing to develop treatments for Parkinson’s disease

Prexton closes €8.7 million in Series A financing to develop treatments for Parkinson’s disease

Prexton Therapeutics, a biopharmaceutical company developing novel therapeutic compounds for the treatment of CNS conditions including Parkinson’s disease, today announces the closing of a Series A financing of €8.7 million ($10 million) co-led by Sunstone Capital and Ysios Capital. [More]
Neurodegenerative disease research using NMR: an interview with Christian Griesinger

Neurodegenerative disease research using NMR: an interview with Christian Griesinger

Christian Griesinger, director of the NMR-based Structural Biology department at the Max-Planck Institute for Biophysical Chemistry, talks about his research into neurodegenerative diseases using NMR to examine the dynamics of disordered proteins. [More]
Saluda Medical receives $10 million in Series B financing

Saluda Medical receives $10 million in Series B financing

Saluda Medical has today announced that it has received $10 million in Series B financing bringing a breakthrough treatment for chronic pain one step closer to reality. [More]
New study finds that statins may not reduce risk for Parkinson's disease

New study finds that statins may not reduce risk for Parkinson's disease

The use of statins may not be associated with lowering risk for Parkinson's disease, according to a new study led by researchers at Penn State College of Medicine and National Institute of Environmental Health Sciences. The findings cast doubts on reports suggesting that the cholesterol-lowering medications may protect against this neurodegenerative brain disorder. [More]

Recent clinical study offers hope for potential Parkinson's disease therapies

Researchers have long sought treatments that can slow the progression of Parkinson's disease. Current treatments have for decades been only symptomatic in nature, supplying the neurotransmitter dopamine, which the dying nerve cells can no longer produce. [More]
Breath test could detect Parkinson’s

Breath test could detect Parkinson’s

The researchers, with funding from Parkinson’s UK and the British Council, will study around 200 people and see if just by looking at their breath they can determine which have Parkinson’s. [More]
Creatine monohydrate disappoints in Parkinson’s disease

Creatine monohydrate disappoints in Parkinson’s disease

Creatine monohydrate fails to live up to its early promise in patients with Parkinson’s disease, show the results of the Long-term Study 1. [More]
'Mad Cow' discovery points to possible neuron killing mechanism behind alzheimer’s and parkinson’s diseases

'Mad Cow' discovery points to possible neuron killing mechanism behind alzheimer’s and parkinson’s diseases

The new study, published recently in the journal Brain, revealed the mechanism of toxicity of a misfolded form of the protein that underlies prion diseases, such as bovine spongiform encephalopathy (“mad cow disease”) and its human equivalent, Creutzfeldt-Jakob disease. [More]

Creatine monohydrate fails to slow clinical progression of Parkinson's disease

Treatment with creatine monohydrate for at least 5 years for patients with early and treated Parkinson disease failed to slow clinical progression of the disease, compared with placebo, according to a study in the February 10 issue of JAMA. [More]
SensiQ Technologies and Inventiva set up a European Center of Excellence in surface plasmon resonance (SPR) technologies

SensiQ Technologies and Inventiva set up a European Center of Excellence in surface plasmon resonance (SPR) technologies

The SPR Center of Excellence is based in Dijon, France. Inventiva’s existing pharmaceutical discovery platform will now include SensiQ SPR technology, which strengthens Inventiva’s current service offering. [More]
Researchers document pathological progress of multiple sclerosis

Researchers document pathological progress of multiple sclerosis

The Centre for Brain Research at the MedUni Vienna is regarded as a world leader in researching the mechanisms involved with multiple sclerosis (MS). Now, in a paper published in the highly respected journal Lancet Neurology, an international team of researchers from Edinburgh, Cleveland and Vienna, under the leadership of Hans Lassmann, Head of the Department of Neuroimmunology at the MedUni Vienna, has for the first time documented the pathological progress of the disease from its early to late stage and also shown that inflammatory and neurodegenerative processes have a role to play. [More]
Movement tracking device can effectively help assess progression of Parkinson's disease

Movement tracking device can effectively help assess progression of Parkinson's disease

A device that measures movement and balance can effectively help assess and track the progression of Parkinson's disease, even when medications are used to reduce Parkinson's symptoms, UT Southwestern Medical Center research found. [More]
Findings could lead to new therapeutic approach to Parkinson's disease

Findings could lead to new therapeutic approach to Parkinson's disease

E.. coli usually brings to mind food poisoning and beach closures, but researchers recently discovered a protein in E.. coli that inhibits the accumulation of potentially toxic amyloids--a hallmark of diseases such as Parkinson's. [More]
Researchers test pocket stimulator on patients with Parkinson's disease

Researchers test pocket stimulator on patients with Parkinson's disease

Parkinson's disease is a slowly degenerative neurological disease that is expressed as impaired motor control, tremors, stiffness and, in later stages, problems with balance. [More]
Disturbed gut microbiome linked to Parkinson’s disease

Disturbed gut microbiome linked to Parkinson’s disease

Research suggests that the intestinal microbiome may be altered in patients with Parkinson’s disease, with some alterations being specific to the motor subtype. [More]
Nonmotor symptoms cluster in Parkinson’s disease patients

Nonmotor symptoms cluster in Parkinson’s disease patients

Nonmotor symptoms tend to appear in specific clusters in patients with Parkinson’s disease and often predate the onset of motor symptoms, research shows. [More]
Two leading biotechnology companies collaborate to gain further understanding of Parkinson’s disease

Two leading biotechnology companies collaborate to gain further understanding of Parkinson’s disease

This week 23andMe (a genetic testing company) and Genentech (medical research company of the Roche Group) agreed a collaboration to undertake whole genome sequencing for 3,000 patients with Parkinson’s disease. The genetic information will be collected by 23andMe and used by Genentech to identify new therapeutic targets for treating Parkinson’s disease. [More]